Cabazitaxel and Radiation For Patients With Prostate Cancer

Inclusion Criteria

• •Conditions for Patient Eligibility
• •Radical prostatectomy for adenocarcinoma of the prostate with at least one of the following:
• •* Extracapsular tumor extension,
• •* Positive surgical margins,
• •* Seminal vesicle invasion
• •* Regional lymph node positive (N1)
• •* Post-prostatectomy PSA of \> 0.1 - \< 2.0 ng/mL at least 6 weeks after prostatectomy and within 30 days of registration in a patient with T2 or T3 disease at prostatectomy.
• •No distant metastases.
• •No prior pelvic or prostate radiation or chemotherapy for prostate cancer.
• •ECOG performance status 0-1.
• •Age\>18.
• •Required entry laboratory parameters within 14 days of study entry: Granulocytes ≥ 1500 cells/mm3; platelet count ≥100,000 cells/mm3, Creatinine ≤ 1.5X upper limit of normal (if creatinine clearance 1.0-1.5x ULN, creatinine clearance will be calculated according to Chronic Kidney Disease Epidemiology Group formula and patients with creatinine clearance \< 60 ml/min should be excluded),19 .Hgb \> 9.0 g/dl, total bilirubin ≤ 1x ULN, and AST or ALT ≤ 2.5 x ULN.
• •Life expectancy of at least 1 year.
• •Must not have uncontrolled severe, intercurrent illness.
• •No concurrent anticancer therapy.
• •Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
• •Signed study-specific consent form prior to study entry.
• •Conditions for Patient Ineligibility